Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA

ALR Technologies announces GluCurve Pet CGM relaunch in Canada

Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment

PureTech clears key FDA milestone for Phase 3 development of deupirfenidone

FDA clears Bristol Myers Squibb's Breyanzi as first CAR T therapy for relapsed or refractory marginal zone lymphoma

J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation

FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness

TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA

Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis

MED-EL cochlear implant FDA approved for children 7 months and older

Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome

Mezzion Pharmaceuticals receives USPTO Notice of Allowance strengthening udenafil exclusivity in Fontan patients

AvenCell Therapeutics receives IND clearance and CTA approval for AVC-203 for the treatment of relapsed/refractory B-cell malignancies

Eli Lilly's Jaypirca receives FDA approval for treatment of adults with relapsed or refractory CLL/SLL previously treated with covalent BTK inhibitor

Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)